Menu Search
Equities

Enlivex Therapeutics Ltd

ENLV:TLV

Enlivex Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (ILa)540.70
  • Today's Change0.00 / 0.00%
  • Shares traded55.23k
  • 1 Year change-46.04%
  • Beta--
Data delayed at least 20 minutes, as of May 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

  • Revenue in USD (TTM)0.00
  • Net income in USD-29.07m
  • Incorporated2012
  • Employees49.00
  • Location
    Enlivex Therapeutics Ltd14 Einstein St.NESS-ZIONA 7403618IsraelISR
  • Phone+972 86623301
  • Fax+972 86312981
  • Websitehttps://www.enlivex.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.